WO2002059377A3 - Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer - Google Patents

Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer Download PDF

Info

Publication number
WO2002059377A3
WO2002059377A3 PCT/US2002/002242 US0202242W WO02059377A3 WO 2002059377 A3 WO2002059377 A3 WO 2002059377A3 US 0202242 W US0202242 W US 0202242W WO 02059377 A3 WO02059377 A3 WO 02059377A3
Authority
WO
WIPO (PCT)
Prior art keywords
breast cancer
methods
diagnosis
compositions
modulators
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/002242
Other languages
French (fr)
Other versions
WO2002059377A2 (en
Inventor
David H Mack
Kurt C Gish
Daniel Afar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PDL Biopharma Inc
Original Assignee
Protein Design Labs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/829,472 external-priority patent/US20040146862A1/en
Application filed by Protein Design Labs Inc filed Critical Protein Design Labs Inc
Priority to AU2002245317A priority Critical patent/AU2002245317A1/en
Priority to CA002440703A priority patent/CA2440703A1/en
Priority to EP02713469A priority patent/EP1425302A2/en
Priority to MXPA03006617A priority patent/MXPA03006617A/en
Priority to JP2002559859A priority patent/JP2005503760A/en
Publication of WO2002059377A2 publication Critical patent/WO2002059377A2/en
Anticipated expiration legal-status Critical
Publication of WO2002059377A3 publication Critical patent/WO2002059377A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Described herein are genes whose expression are up-regulated or down-regulated in breast cancer. Related methods and compositions that can be used for diagnosis and treatment of breast cancer are disclosed. Also described herein are methods that can be used to identify modulators of breast cancer.
PCT/US2002/002242 2001-01-24 2002-01-24 Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer Ceased WO2002059377A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2002245317A AU2002245317A1 (en) 2001-01-24 2002-01-24 Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer
CA002440703A CA2440703A1 (en) 2001-01-24 2002-01-24 Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer
EP02713469A EP1425302A2 (en) 2001-01-24 2002-01-24 Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer
MXPA03006617A MXPA03006617A (en) 2001-01-24 2002-01-24 Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer.
JP2002559859A JP2005503760A (en) 2001-01-24 2002-01-24 Breast cancer diagnosis method, composition and breast cancer modulator screening method

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US26396501P 2001-01-24 2001-01-24
US60/263,965 2001-01-24
US26592801P 2001-02-02 2001-02-02
US60/265,928 2001-02-02
US28269801P 2001-04-09 2001-04-09
US60/282,698 2001-04-09
US09/829,472 US20040146862A1 (en) 2000-03-15 2001-04-09 Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer
US09/829,472 2001-04-09
US28859001P 2001-05-04 2001-05-04
US60/288,590 2001-05-04
US29444301P 2001-05-29 2001-05-29
US60/294,443 2001-05-29

Publications (2)

Publication Number Publication Date
WO2002059377A2 WO2002059377A2 (en) 2002-08-01
WO2002059377A3 true WO2002059377A3 (en) 2004-04-01

Family

ID=27559443

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/002242 Ceased WO2002059377A2 (en) 2001-01-24 2002-01-24 Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer

Country Status (6)

Country Link
EP (1) EP1425302A2 (en)
JP (1) JP2005503760A (en)
AU (1) AU2002245317A1 (en)
CA (1) CA2440703A1 (en)
MX (1) MXPA03006617A (en)
WO (1) WO2002059377A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9562049B2 (en) 2012-12-21 2017-02-07 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US9567340B2 (en) 2012-12-21 2017-02-14 Medimmune Limited Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases

Families Citing this family (153)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7598226B2 (en) 1998-12-28 2009-10-06 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6844325B2 (en) 1998-12-28 2005-01-18 Corixa Corporation Compositions for the treatment and diagnosis of breast cancer and methods for their use
US6969518B2 (en) 1998-12-28 2005-11-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
AU1807401A (en) 1999-11-30 2001-06-12 Corixa Corporation Compositions and methods for therapy and diagnosis of breast cancer
JP2003523207A (en) 2000-01-25 2003-08-05 ジェネンテック・インコーポレーテッド LIV-1-related proteins, polynucleotides encoding them, and their use in treating cancer
US7358353B2 (en) 2000-08-22 2008-04-15 Agensys, Inc. Nucleic acid and corresponding protein named 158P1D7 useful in the treatment and detection of bladder and other cancers
CA2420543C (en) 2000-08-22 2013-04-02 Agensys, Inc. Nucleic acid and corresponding protein named 158p1d7 useful in the treatment and detection of bladder and other cancers
US7645441B2 (en) * 2000-12-22 2010-01-12 Sagres Discovery Inc. Compositions and methods in cancer associated with altered expression of PRLR
US7271240B2 (en) 2001-03-14 2007-09-18 Agensys, Inc. 125P5C8: a tissue specific protein highly expressed in various cancers
US7713526B2 (en) 2001-05-01 2010-05-11 The Regents Of The University Of California Wnt and frizzled receptors as targets for immunotherapy in head and neck squamous cell carcinomas
US7682607B2 (en) 2001-05-01 2010-03-23 The Regents Of The University Of California Wnt and frizzled receptors as targets for immunotherapy in head and neck squamous cell carcinomas
EP1410013A4 (en) * 2001-06-21 2006-02-01 Millennium Pharm Inc COMPOSITIONS, NEEDS AND METHODS FOR THE IDENTIFICATION, EVALUATION, PREVENTION AND TREATMENT OF BREAST CANCERS AND OVARIA
AU2008202004A1 (en) * 2001-09-18 2008-05-29 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
ES2431929T3 (en) 2001-09-18 2013-11-28 Genentech, Inc. Compositions and procedures for the diagnosis and treatment of tumors
ATE356223T1 (en) 2001-09-25 2007-03-15 Japan President Univ Tokyo GENE AND PROTEIN RELATED TO HEPATOCELLULAR CARCINOMA
EP1310552B1 (en) 2001-11-09 2007-06-13 Proteologics, Inc. Posh nucleic acids, polypeptides and related methods
DE10296200D2 (en) * 2001-12-21 2004-11-04 Biovision Ag Methods for diagnosing breast cancer, associated peptides and their uses
AU2003213672A1 (en) * 2002-03-04 2003-09-22 Avalon Pharmaceuticals Cancer-linked gene as target for chemotherapy
DK2258872T3 (en) 2002-03-13 2013-11-18 Genomic Health Inc Gene expression profiling in tumor tissue biopsies
AU2003244191A1 (en) * 2002-06-26 2004-01-19 Takeda Pharmaceutical Company Preventives/remedies for cancer
US7851213B2 (en) * 2002-07-03 2010-12-14 Sanofi Pasteur Limited Tumor antigens BFA4 and BCY1 for prevention and / or treatment of cancer
AU2003243151A1 (en) * 2002-08-16 2004-03-03 Agensys, Inc. Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
AU2003278812A1 (en) * 2002-09-16 2004-04-30 Exelixis, Inc. FLJ20647s AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE
GB0222787D0 (en) * 2002-10-02 2002-11-06 Univ Liverpool Metastasis inducing compounds
WO2004046386A1 (en) 2002-11-15 2004-06-03 Genomic Health, Inc. Gene expression profiling of egfr positive cancer
GB0227908D0 (en) * 2002-11-29 2003-01-08 Univ London Cancer related methods and means
US20040231909A1 (en) 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
EP2343315A3 (en) * 2003-02-10 2011-11-23 Agensys, Inc. Nucleic acid and corresponding protein named 158P1D7 useful in the treatment and detection of bladder and other cancers
CA2516553C (en) 2003-02-20 2013-04-16 Genomic Health, Inc. Use of intronic rna to measure gene expression
WO2004079014A2 (en) * 2003-03-04 2004-09-16 Arcturus Bioscience, Inc. Signatures of er status in breast cancer
WO2004091383A2 (en) * 2003-04-01 2004-10-28 Genzyme Corporation Breast endothelial cell expression patterns
EP1613966A2 (en) * 2003-04-08 2006-01-11 Colotech A/S A method for detection of colorectal cancer in human samples
WO2004099779A1 (en) * 2003-05-05 2004-11-18 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human transmembrane serine protease 3 (tmprss3)
US8207314B2 (en) * 2003-05-16 2012-06-26 Sanofi Pasteur Limited Tumor antigens for prevention and/or treatment of cancer
ATE449842T1 (en) 2003-05-28 2009-12-15 Takeda Pharmaceutical ANTI-BAMBI ANTIBODIES OR RNA FOR DIAGNOSIS AND THERAPY OF COLON OR LIVER CANCER
JP2007504842A (en) * 2003-05-29 2007-03-08 ミレニアム ファーマシューティカルズ， インコーポレイテッド Compositions, kits and methods for identification, evaluation, prevention and treatment of breast cancer
CA2524708C (en) 2003-06-06 2009-10-06 F. Hoffmann-La Roche Ag Use of protein cellular retinoic acid-binding protein ii (crabp ii) as marker for breast cancer
US20050100933A1 (en) * 2003-06-18 2005-05-12 Arcturus Bioscience, Inc. Breast cancer survival and recurrence
EP3170906B1 (en) 2003-06-24 2018-08-22 Genomic Health, Inc. Prediction of likelihood of cancer recurrence
EP3330875B1 (en) 2003-07-10 2021-12-01 Genomic Health, Inc. Expression profile algorithm and test for prognosing breast cancer recurrence
WO2005005471A2 (en) 2003-07-11 2005-01-20 Develogen Aktiengesellschaft Use of dg153 secreted protein products for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome
WO2005015231A1 (en) * 2003-08-08 2005-02-17 Roche Diagnostics Gmbh Use of protein spermidine synthase (spee) as a marker for colorectal cancer
ATE393393T1 (en) * 2003-10-15 2008-05-15 Hoffmann La Roche USE OF THE PROTEIN SPEE AS A MARKER FOR BREAST CANCER
WO2005040811A1 (en) * 2003-10-15 2005-05-06 Roche Diagnostics Gmbh Use of protein tip47 as a marker for breast cancer
EP3434275A1 (en) 2003-11-06 2019-01-30 Seattle Genetics, Inc. Assay for cancer cells based on the use of auristatin conjugates with antibodies
CA2551267C (en) 2003-12-23 2012-05-01 Genomic Health, Inc. Universal amplification of fragmented rna
JP4847873B2 (en) * 2004-01-09 2011-12-28 チルドレンズ メディカル センター コーポレーション Methods for diagnosing and prognosing cancer of epithelial origin
TWI350373B (en) 2004-01-23 2011-10-11 Oncotherapy Science Inc Methods of detecting methyl transferase activity and methods of screening formethyl transferase activity modulators
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
US7871769B2 (en) 2004-04-09 2011-01-18 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
US7332281B2 (en) 2004-04-27 2008-02-19 Sagres Discovery, Inc. Therapeutic targets in cancer
EP1747236A1 (en) * 2004-05-12 2007-01-31 Institut National De La Sante Et De La Recherche Medicale (Inserm) Nectin 4(n4) as a marker for cancer prognosis
WO2005114213A2 (en) * 2004-05-21 2005-12-01 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled receptor npy1 (npy1)
MXPA06014065A (en) 2004-06-01 2007-01-31 Genentech Inc Antibody drug conjugates and methods.
US7587279B2 (en) 2004-07-06 2009-09-08 Genomic Health Method for quantitative PCR data analysis system (QDAS)
EP1621637A1 (en) * 2004-07-30 2006-02-01 Institut Curie ppGalNac-T6 mRNA or peptide as a new marker for the detection of cancer cells
CN102443627B (en) * 2004-08-10 2014-10-29 加的夫生物学有限公司 Kit for the prognosis of breast cancer
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
ES2579805T3 (en) 2004-09-23 2016-08-16 Genentech, Inc. Antibodies and conjugates engineered with cysteine
CA2585561C (en) 2004-11-05 2018-07-17 Genomic Health, Inc. Esr1, pgr, bcl2 and scube2 group score as indicators of breast cancer prognosis and prediction of treatment response
CA2585571C (en) 2004-11-05 2020-01-21 Genomic Health, Inc. Predicting response to chemotherapy using gene expression markers
WO2006069449A1 (en) * 2004-12-29 2006-07-06 The University Of British Columbia Chemokine receptor-independent immunomodulatory and anti-proliferative activity
WO2006092958A1 (en) * 2005-02-28 2006-09-08 Oncotherapy Science, Inc. Breast cancer related gene znfn3a1
WO2006121208A1 (en) * 2005-05-12 2006-11-16 Oncotherapy Science, Inc. Polymorphisms of the e2f-1 binding element and methods of determining cancer susceptibility
TW200741009A (en) 2005-07-01 2007-11-01 Oncotherapy Science Inc Methods of modulating SMYD3 for treatment of cancer
DE602006021315D1 (en) * 2005-07-29 2011-05-26 Oncotherapy Science Inc GENE AND POLYPEPTIDE IN CONNECTION WITH BREAST CANCER
AU2006321841C1 (en) 2005-12-08 2013-01-24 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to protein tyrosine kinase 7 ( PTK7 ) and their use
EP1806587A1 (en) * 2006-01-07 2007-07-11 Université de Liège An in-vitro method for screening accessible biological markers in pathologic tissues
WO2007120753A2 (en) * 2006-04-11 2007-10-25 Corixa Corporation Methods, compositions, and kits for the detection and monitoring of bladder cancer
US7851144B2 (en) 2006-08-18 2010-12-14 The University Of Washington Compositions and methods for detecting cancer
WO2008152816A1 (en) 2007-06-14 2008-12-18 Oncotherapy Science, Inc. Methods of identifying agents that modulate methylation of vegfr1 by smyd3
NO2280721T3 (en) 2008-04-17 2018-04-14
WO2010009124A2 (en) 2008-07-15 2010-01-21 Genentech, Inc. Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds
EP2214019A1 (en) * 2009-01-28 2010-08-04 Externautics S.p.A. Tumor markers and methods of use thereof
JP2013504585A (en) 2009-09-09 2013-02-07 セントローズ， エルエルシー Extracellular targeted drug complex
WO2011062997A2 (en) 2009-11-17 2011-05-26 Musc Foundation For Research Development Human monoclonal antibodies to human nucleolin
WO2011130598A1 (en) 2010-04-15 2011-10-20 Spirogen Limited Pyrrolobenzodiazepines and conjugates thereof
WO2011140662A1 (en) * 2010-05-13 2011-11-17 The Royal Institution For The Advancement Of Learning / Mcgill University Cux1 signature for determination of cancer clinical outcome
SG185428A1 (en) 2010-06-08 2012-12-28 Genentech Inc Cysteine engineered antibodies and conjugates
EP2621526B1 (en) 2010-09-29 2018-06-06 Agensys, Inc. Antibody drug conjugates (adc) that bind to 191p4d12 proteins
WO2012074757A1 (en) 2010-11-17 2012-06-07 Genentech, Inc. Alaninyl maytansinol antibody conjugates
US20120269418A1 (en) * 2011-04-22 2012-10-25 Ge Global Research Analyzing the expression of biomarkers in cells with clusters
US8679767B2 (en) 2011-05-12 2014-03-25 Genentech, Inc. Multiple reaction monitoring LC-MS/MS method to detect therapeutic antibodies in animal samples using framework signature peptides
PT2750713E (en) 2011-10-14 2016-01-20 Genentech Inc Pyrrolobenzodiazepines and conjugates thereof
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
SG10201912773TA (en) 2012-08-23 2020-02-27 Agensys Inc Antibody drug conjugates (adc) that bind to 158p1d7 proteins
US9931414B2 (en) 2012-10-12 2018-04-03 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
ES2738310T3 (en) 2012-10-12 2020-01-21 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
WO2014057120A1 (en) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Pyrrolobenzodiazepine-antibody conjugates
ES2649990T3 (en) 2012-10-12 2018-01-16 Medimmune Limited Anti-CD22-pyrrolobenzodiazepine antibody conjugates
NZ707486A (en) 2012-10-12 2018-09-28 Adc Therapeutics Sa Pyrrolobenzodiazepine - anti-psma antibody conjugates
EP2906296B1 (en) 2012-10-12 2018-03-21 ADC Therapeutics SA Pyrrolobenzodiazepine-antibody conjugates
WO2014057114A1 (en) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Pyrrolobenzodiazepine-anti-psma antibody conjugates
AU2014244245C1 (en) 2013-03-13 2018-04-19 Genentech, Inc. Pyrrolobenzodiazepines and conjugates thereof
CN105142674B (en) 2013-03-13 2018-11-13 麦迪穆有限责任公司 Pyrrolobenzodiazepines and their conjugates
CA2905181C (en) 2013-03-13 2020-06-02 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof for providing targeted therapy
JP6993084B2 (en) 2013-08-12 2022-02-03 ジェネンテック， インコーポレイテッド 1- (Chloromethyl) -2,3-dihydro-1H-benzo [E] indole dimer antibody-drug conjugate compound, and method of use and treatment
EP3054985B1 (en) 2013-10-11 2018-12-26 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
EP3054986B1 (en) 2013-10-11 2019-03-20 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
EP3054983B1 (en) 2013-10-11 2019-03-20 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
CA2928952A1 (en) 2013-12-16 2015-06-25 Genentech, Inc. Peptidomimetic compounds and antibody-drug conjugates thereof
EP3082876B1 (en) 2013-12-16 2018-01-17 Genentech, Inc. 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
UA118113C2 (en) 2013-12-16 2018-11-26 Дженентек, Інк. Peptidomimetic compounds and antibody-drug conjugates thereof
US10188746B2 (en) 2014-09-10 2019-01-29 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
TW201625688A (en) 2014-09-12 2016-07-16 建南德克公司 Cysteine engineered antibodies and conjugates
US10149913B2 (en) 2014-09-12 2018-12-11 Genentech, Inc. Anthracycline disulfide intermediates, antibody-drug conjugates and methods
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
JP2017533887A (en) 2014-09-17 2017-11-16 ジェネンテック， インコーポレイテッド Pyrrolobenzodiazepines and their antibody disulfide conjugates
EP3223854A1 (en) 2014-11-25 2017-10-04 ADC Therapeutics SA Pyrrolobenzodiazepine-antibody conjugates
MX2017007169A (en) 2014-12-03 2018-05-02 Genentech Inc Quaternary amine compounds and antibody-drug conjugates thereof.
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
KR102111338B1 (en) 2015-10-02 2020-05-15 제넨테크, 인크. Pyrrolobenzodiazepine antibody drug conjugates and methods of use thereof
WO2017064675A1 (en) 2015-10-16 2017-04-20 Genentech, Inc. Hindered disulfide drug conjugates
EP3365025B1 (en) 2015-10-20 2020-07-15 Genentech, Inc. Calicheamicin-antibody-drug conjugates and methods of use
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
US20170315132A1 (en) 2016-03-25 2017-11-02 Genentech, Inc. Multiplexed total antibody and antibody-conjugated drug quantification assay
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
CN118436801A (en) 2016-05-20 2024-08-06 豪夫迈·罗氏有限公司 PROTAC antibody conjugates and methods of use thereof
JP7022080B2 (en) 2016-05-27 2022-02-17 ジェネンテック， インコーポレイテッド Biochemical analytical methods for the characterization of site-specific antibody-drug conjugates
US10639378B2 (en) 2016-06-06 2020-05-05 Genentech, Inc. Silvestrol antibody-drug conjugates and methods of use
EP3496763B1 (en) 2016-08-11 2026-04-01 Genentech, Inc. Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
EP3522933B1 (en) 2016-10-05 2021-12-15 F. Hoffmann-La Roche AG Methods for preparing antibody drug conjugates
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
US11160872B2 (en) 2017-02-08 2021-11-02 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
EP3612537B1 (en) 2017-04-18 2022-07-13 Medimmune Limited Pyrrolobenzodiazepine conjugates
CN110536703B (en) 2017-04-20 2024-07-12 Adc治疗有限公司 Combination therapy using anti-AXL antibody-drug conjugates
UA127900C2 (en) 2017-06-14 2024-02-07 Ейдісі Терапьютікс Са Dosage regimes for the administration of an anti-cd19 adc
RS62928B1 (en) 2017-08-18 2022-03-31 Medimmune Ltd Pyrrolobenzodiazepine conjugates
US10301319B2 (en) 2017-09-20 2019-05-28 Ph Pharma Co., Ltd. Thailanstatin analogs
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
WO2019189990A1 (en) * 2018-03-27 2019-10-03 신일제약주식회사 Breast cancer diagnosis composition using multiple autoantibodies and breast cancer diagnosis kit using same
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
TW202037381A (en) 2018-10-24 2020-10-16 瑞士商赫孚孟拉羅股份公司 Conjugated chemical inducers of degradation and methods of use
US12257340B2 (en) 2018-12-03 2025-03-25 Agensys, Inc. Pharmaceutical compositions comprising anti-191P4D12 antibody drug conjugates and methods of use thereof
EP3894427A1 (en) 2018-12-10 2021-10-20 Genentech, Inc. Photocrosslinking peptides for site specific conjugation to fc-containing proteins
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
ES2967878T3 (en) 2019-03-15 2024-05-06 Medimmune Ltd Azetidobenzodiazepine dimers and conjugates comprising them for use in the treatment of cancer
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
WO2022044788A1 (en) * 2020-08-28 2022-03-03 学校法人埼玉医科大学 Double-stranded nucleic acid molecule, dna, vector, female cancer cell growth inhibition agent, female cancer tumor formation inhibition agent, pharmaceutical, and use of long-chain noncoding rna
CN116219021B (en) * 2020-12-30 2025-12-16 上海奕谱生物科技有限公司 Tumor marker located on chromosome 10 and application thereof
CN117980327A (en) 2021-11-03 2024-05-03 杭州多禧生物科技有限公司 Specific conjugation of antibodies
EP4569118A1 (en) * 2022-08-08 2025-06-18 Université de Montréal Novel antigens for cancer and uses thereof
EP4637833A2 (en) 2022-12-23 2025-10-29 Genentech, Inc. Cereblon degrader conjugates, and uses thereof
AU2024257248A1 (en) 2023-04-17 2025-11-06 Peak Bio, Inc. Antibodies and antibody-drug conjugates and methods of use and synthetic processes and intermediates
WO2026006689A2 (en) 2024-06-28 2026-01-02 Firefly Bio, Inc. Bcl-xl degrader antibody conjugates and uses thereof
WO2026006688A2 (en) 2024-06-28 2026-01-02 Firefly Bio, Inc. Degrader antibody conjugates and uses thereof
CN120539414B (en) * 2025-07-31 2025-09-19 安徽医科大学 Application of FIGN protein in cytoplasm as a marker in the preparation of diagnostic products for lung adenocarcinoma and/or breast cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998045328A2 (en) * 1997-04-09 1998-10-15 Corixa Corporation Compositions and methods for the treatment and diagnosis of breast cancer
WO1999033869A2 (en) * 1997-12-24 1999-07-08 Corixa Corporation Compounds for immunotherapy and diagnosis of breast cancer and methods for their use
WO2000022130A2 (en) * 1998-10-15 2000-04-20 Chiron Corporation Metastatic breast and colon cancer regulated genes

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998045328A2 (en) * 1997-04-09 1998-10-15 Corixa Corporation Compositions and methods for the treatment and diagnosis of breast cancer
WO1999033869A2 (en) * 1997-12-24 1999-07-08 Corixa Corporation Compounds for immunotherapy and diagnosis of breast cancer and methods for their use
WO2000022130A2 (en) * 1998-10-15 2000-04-20 Chiron Corporation Metastatic breast and colon cancer regulated genes

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BERTUCCI F ET AL: "Gene expression profiling of primary breast carcinomas using arrays of cancidate genes", HUMAN MOLECULAR GENETICS, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 9, no. 20, 2000, pages 2981 - 2991, XP002225994, ISSN: 0964-6906 *
BURGER A M ET AL: "Detection of novel genes that are up-regulated (Di12) or down-regulated (T1A12) with disease progression in breast cancer", MEDLINE, XP002217698 *
DATABASE SWISSPROT [online] 1 May 1992 (1992-05-01), "ODPA human", XP002254869, accession no. EBI Database accession no. P08559 *
MARTIN K J ET AL: "LINKING GENE EXPRESSION PATTERNS TO THERAPEUTIC GROUPS IN BREAST CANCER", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 60, no. 8, 15 April 2000 (2000-04-15), pages 2232 - 2238, XP001026395, ISSN: 0008-5472 *
WATSON M A ET AL: "ISOLATION OF DIFFERENTIALLY EXPRESSED SEQUENCE TAGS FROM HUMAN BREAST CANCER", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 54, no. 17, 1 September 1994 (1994-09-01), pages 4598 - 4602, XP000576043, ISSN: 0008-5472 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9562049B2 (en) 2012-12-21 2017-02-07 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US9567340B2 (en) 2012-12-21 2017-02-14 Medimmune Limited Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases

Also Published As

Publication number Publication date
JP2005503760A (en) 2005-02-10
CA2440703A1 (en) 2002-08-01
AU2002245317A1 (en) 2002-08-06
WO2002059377A2 (en) 2002-08-01
EP1425302A2 (en) 2004-06-09
MXPA03006617A (en) 2004-12-02

Similar Documents

Publication Publication Date Title
WO2002102235A3 (en) Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
WO2003025138A3 (en) Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer
WO2003042661A3 (en) Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
WO2003003906A3 (en) Diagnostic and screening methods for bladder cancer
WO2002030268A3 (en) Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer
WO2004048938A3 (en) Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators
WO2004073657A3 (en) Methods of diagnosis of cancer and other diseases, composition and methods of screening for modulators of cancer and other diseases
WO2002098358A3 (en) Methods of diagnosis and treatment of androgen-dependent prostate cancer, prostate cancer undergoing androgen-withdrawal, and androgen-independent prostate cancer
EP2014669A3 (en) Compositions and methods for cancer
WO2004008147A3 (en) Diagnosis and prevention of cancer cell invasion
WO2003004989A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
AU2002245317A1 (en) Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer
AU2003300368A8 (en) Methods and compositions for the diagnosis, prognosis, and treatment of cancer
WO2003087831A3 (en) Proteins involved in breast cancer
AU2001229340A1 (en) Genes compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
WO2006029219A3 (en) Human monoclonal anti-ctla4 antibodies in cancer treatment
WO2004106495A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
EP1900827A3 (en) Methods and compositions for the prediction, diagnosis, prognosis, prevention and treatment of malignant neoplasia
AU2002251366A1 (en) Proteins, genes and their use for diagnosis and treatment of breast cancer
WO2003045230A3 (en) Novel compositions and methods for cancer
WO2008060945A3 (en) Diagnosis and treatment of breast cancer
WO2003057146A3 (en) Novel compositions and methods for cancer
WO2003053224A3 (en) Novel compositions and methods for cancer
WO2003076610A3 (en) Variants of human kallikrein-2 and kallikrein-3 and uses thereof
AU2002313726A1 (en) Compositions and methods for the therapy and diagnosis of breast cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/006617

Country of ref document: MX

Ref document number: 2002559859

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002713469

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2440703

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 2002713469

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2002713469

Country of ref document: EP